The Filing Desk

Concord Medical Services

CCM · NYSE · Health Care · Financials, fiscal 2016 to 2025

CCM · Last close · November 19, 2026
$3.59

Concord Medical Services' revenue rose 19.9% to CN¥460 million in fiscal 2025. Its operating margin was −56.8%, up from −138.6% a year earlier. Free cash flow was −CN¥258 million.

Concord Medical Services Holdings Ltd Latest fiscal year ended December 31, 2025 20-F filed April 29, 2026 · 0001104659-26-050692 Updated
Revenue
CN¥460M
19.9%
Operating margin
−56.8%
81.8 pts
Net income
−CN¥93M
 
Free cash flow
−CN¥258M
 
Return on capital
−4.1%
4.5 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

About these figures. Concord Medical Services is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model. Its figures are in CNY, as it reports them: they aren't converted to US dollars.

What Concord Medical Services does

Concord Medical Services runs cancer hospitals and clinics in China and supplies cancer-treatment equipment to other hospitals there. At the end of 2025 it had four hospitals and clinics of its own: a full cancer hospital in Guangzhou, two clinics and an imaging center in Shanghai. They offer screening, scans, radiation therapy, chemotherapy, surgery and care after treatment. The Guangzhou hospital opened a proton therapy center, a precise form of radiation treatment, in December 2024.

The company reports two businesses. The hospital business, its own hospitals and clinics, brought in RMB373.9 million in 2025. The network business leases radiation and imaging machines, such as linear accelerators and PET-CT scanners, to partner hospitals, runs the non-medical side of these centers and takes an agreed share of each center's revenue; it brought in RMB86.6 million, down as the company stops renewing expired leases. At the end of 2025 it served eight such centers in six hospitals. Total revenue was RMB460.5 million.

The company is building a second cancer hospital in Shanghai, with 400 beds, which it expects to open in 2027, and runs an online hospital for cancer patients. It works with the University of Texas MD Anderson Cancer Center, which advises its hospitals under a consulting agreement. It has made losses, and its 20-F says there is substantial doubt about its ability to continue as a going concern.

Its biggest risks, as it describes them

  • Building and opening new cancer hospitals and proton centers takes a lot of money, and new hospitals may take a long time to make a profit.
  • It has made losses, burned cash and carries large debts, which raise doubt about its ability to keep operating.
  • Much of its revenue comes from a few partner hospitals and from Shanghai and Guangzhou, so trouble in one can hurt it badly.
  • It may not hire and keep enough qualified doctors and other medical staff.
  • It works in a heavily regulated industry in China, where some prices are set by public insurance rules.
From Concord Medical Services's annual report on Form 20-F, filed April 29, 2026, in our words; the 20-F has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
CNY billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
CNY billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Concord Medical Services lost money in fiscal 2025: a net loss of CN¥93 million.

Diluted earnings per share
CNY per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
CNY billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
CNY billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments15715858351298
Debt incl. finance leases2,4782,9843,0363,7263,447
Net debt (negative means net cash)2,3202,8262,9783,3763,149
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−6.2x−4.4x−2.8x−2.8x−1.7x
Current ratio0.7x0.7x0.3x0.5x0.5x
Quick ratio0.7x0.6x0.3x0.5x0.5x
CNY millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
CNY billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
CNY billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
CNY billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score5 of 92 of 96 of 9
Rule of 40−58.6%−171.4%−36.1%
Altman Z''−3.72−3.43−3.09
Accruals ratio−0.3%1.4%1.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assetsFailFailPass
Current ratio roseFailPassPass
Share count didn't risePassPassPass
Gross margin rosePassFailPass
Revenue rose relative to assetsPassFailPass
F-score5 of 92 of 96 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Concord Medical Services side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Concord Medical ServicesFY2519.9%−56.8%−56.1%−4.1%—6
GeneDxFY2540.0%−3.1%3.3%−5.3%—6Compare
Starling OncologyFY2527.8%−7.2%−5.5%−75.7%—3Compare
VeracyteFY2516.0%11.2%24.5%6.1%−4.6x6Compare
PomDoctorFY2516.7%−29.7%−37.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue455331191198223486472537384460
Revenue growth−26.2%−27.3%−42.3%3.9%12.4%117.8%−2.8%13.8%−28.6%19.9%
Gross profit1689820−1613−57−152−77−7926
Research and development——————————
Operating income−169−212−299−437−316−458−525−463−532−262
Net income−262−284−235−307−310−271−490−298−308−93
Diluted EPS (CNY)−2.00−2.19−2.76−4.24−5.11−6.26−3.74−2.27−2.35−0.71
Diluted shares (millions)131130130130131131131131131131
Cash flow
Cash from operations−7827−39−195−230−359−217−276−398−202
Capital expenditure799116623316827922311315156
Free cash flow−157−65−204−428−398−638−440−389−549−258
Dividends paid286000000000
Share buybacks30000000000
Acquisitions260529421820000
Stock-based compensation81211212115−60——
Balance sheet at fiscal year end
Cash and short-term investments—984557433415715858351298
Debt incl. finance leases8617619381,6202,1172,4782,9843,0363,7263,447
Total assets3,2293,4654,5854,2975,3346,2306,0056,0546,7266,547
Total liabilities1,9972,4502,3122,4082,9343,4863,9894,3075,1094,697
Shareholders' equity1,166934437−123−663−1,370−1,864−2,122−2,280−2,103
Margins and ratios
Gross margin37.0%29.6%10.3%−8.0%5.9%−11.7%−32.3%−14.3%−20.6%5.6%
Operating margin−37.1%−64.0%−156.8%−220.4%−141.7%−94.4%−111.2%−86.2%−138.6%−56.8%
Net margin−57.5%−85.9%−123.0%−154.8%−139.0%−55.9%−103.7%−55.4%−80.3%−20.1%
Free cash flow margin−34.5%−19.5%−107.0%−215.8%−178.4%−131.4%−93.1%−72.5%−142.9%−56.1%
Rule of 40 (growth + FCF margin)−60.7%−46.8%−149.3%−211.9%−165.9%−13.7%−95.9%−58.6%−171.4%−36.1%
Return on capital——−18.7%−34.1%−22.6%−34.5%−13.3%−7.7%−8.7%−4.1%
Return on equity−20.5%−27.1%−34.2%———————
Return on assets−7.7%−8.5%−5.8%−6.9%−6.4%−4.7%−8.0%−4.9%−4.8%−1.4%
Net debt to EBITDA——————————
CNY millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, CNY millions)
Source: Concord Medical Services' Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Concord Medical Services.